GH treatment in pediatric Down syndrome: a systematic review and mini meta-analysis

Frontiers in Endocrinology

Endocrinology

Arkadi Bollotin¹  Guy Yalovitsky¹  Raphael Nowak¹  Shai Tamam²  Dganit Walker³  Lior Carmon⁴  Neta Loewenthal⁴  Alon Haim⁴  David Shaki⁴  Odeya David⁴  Eli Hershkovitz⁴ 

[1] Faculty of Health Sciences, Ben-Gurion University, Beer Sheva, Israel;Library of Life Sciences and Medicine, Tel Aviv University, Tel Aviv, Israel;Pediatric Endocrinology Unit, Soroka University Medical Center, Beer Sheva, Israel;Pediatric Endocrinology Unit, Soroka University Medical Center, Beer Sheva, Israel;Faculty of Health Sciences, Ben-Gurion University, Beer Sheva, Israel;

关键词: growth hormone;    GH;    rGH treatment;    Down syndrome;    insulin-like growth factor 1;    IGF1;   

DOI  :  10.3389/fendo.2023.1135768

 received in 2023-01-01, accepted in 2023-04-05,  发布年份 2023

来源: Frontiers

【 摘 要 】

ObjectiveTo analyze and determine the safety and efficacy of growth hormone (GH) treatment in Down syndrome (DS) pediatric patients and to weigh ethical aspects involved.DesignSystematic review and mini meta-analysis of the literature.MethodsA search was performed in PubMed, Embase, Scopus, and PsycINFO through August 2022. Eligible studies included those who answered at least one of the following two questions: 1) What is the effect of growth hormone treatment in children with Down syndrome? 2) What are the ethical arguments in favor and against growth hormone treatment for children with Down syndrome? Multiple reviewers independently screened each article for eligibility.ResultsIn total sixteen reports detailed medical effects of GH treatment in pediatric DS patients and eight studies dealt with ethical aspects of GH treatment. Treatment with GH resulted in significantly higher growth velocity in patients with DS. The ethical complexity is great but does not present insurmountable difficulties to the therapeutic option.ConclusionsAs GH treatment is safe and effective for short-term height growth, GH therapy should be considered in long-term treatment of DS children.

【 授权许可】

Unknown   
Copyright © 2023 Shaki, Hershkovitz, Tamam, Bollotin, David, Yalovitsky, Loewenthal, Carmon, Walker, Nowak and Haim